Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jose Gustavo Nuñez Cerrillo"'
Autor:
Svetlana V Doubova, Adriana Monroy, Saúl Eduardo Contreras Sánchez, Rocío Grajales Álvarez, Wendy Jazmín Martínez Pineda, Jose Gustavo Nuñez Cerrillo, Rita Zalapa Velázquez, Ingrid Patricia Martinez Vega, Ricardo Villalobos Valencia, Abdel Karim Dip Borunda, Lorena Lio Mondragón, Alma Diana Huerta López, Valeria Mendoza Ortiz, Víctor Javier Vázquez Zamora, Álvaro José Montiel Jarquín, Arturo García Galicia, Enrique Isay Talamantes Gómez, Roberto Sánchez Reyes, Jaqueline Aguirre Gómez, María Eugenia Ayala Anzures, Marta Zapata Tarrés, Hannah H. Leslie
Publikováno v:
BMJ Open, Vol 14, Iss 6 (2024)
Objectives This study aimed to explore the acceptability, feasibility, usability, and preliminary effect of an electronic patient-reported outcome (ePRO) intervention for patients with breast cancer in Mexico.Design We conducted a multimethod non-ran
Externí odkaz:
https://doaj.org/article/1ba1ef4b07a543d085e7327608fb27b3
Autor:
Hannah H Leslie, Svetlana V Doubova, Saúl Eduardo Contreras Sánchez, Rocío Grajales Álvarez, Abdel Krim Dip Borunda, Wendy Jazmín Martínez Pineda, Jose Gustavo Nuñez Cerrillo, Fernando Silva Bravo, Rita Zalapa Velázquez, Marcos Gutiérrez De la Barrera
Publikováno v:
BMJ Open, Vol 13, Iss 11 (2023)
Introduction Nearly 30 000 Mexican women develop breast cancer annually, frequently presenting unmet supportive care needs. In high-income countries, incorporating electronic patient-reported outcomes (ePROs) into cancer care has demonstrated potenti
Externí odkaz:
https://doaj.org/article/d5f275d1f5f941fea5b9ed13f1f52b7e
Autor:
Jose Gustavo Nuñez Cerrillo, Rodrigo Fernando Riera Sala, Juan Carlos Silva Godinez, Maritza Peña Campos, Raul Rogelio Trejo rosales
Publikováno v:
Journal of Clinical Oncology. 37:e20073-e20073
e20073 Background: Malignant pleural mesothelioma (MPM) is an infrequent entity with a poor prognosis. Standard first line chemotherapy therapy is based on pemetrexed and cisplatin, however, there is no established standard second-line therapy. We re